Skip Navigation

Your Environment. Your Health.

Person Details

Superfund Research Program

Clement E. Furlong

University of Washington
Department of Medicine and Genome Sciences
Division of Medical Genetics
Seattle, WA 98195
Phone: (206) 543-1193
Fax: (206) 543-3050
Email: clem@u.washington.edu

Projects

Research Briefs

Patents

Publications

2016

  • Marsillach J, Costa LG, Furlong CE. 2016. Paraoxonase-1 and early life environmental exposures. Ann Glob Health(in press)

2015

2014

2013

2012

2011

2010

2009

2008

2007

  • Furlong CE. 2007. Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds. J Biochem Mol Toxicol21(4):197-205.

2006

  • Costa LG, Cole TB, Furlong CE. 2006. Gene-environment interactions: Paraoxonase (PON1) and sensitivity to organophosphate toxicity. LabMedicine37(2):109-113.
  • Costa LG, Cole TB, Furlong CE. 2006. Genetic ponymorphisms of human paraoxonase (PON1) and susceptibility to organophosphorous insecticide toxicity. In: 28th International Congress on Occupational Health (ICOH); May 11-16. Milan, Italy.
  • Costa LG, Cole TB, Furlong CE. 2006. PON1 and organophosphate toxicity. In: 2nd International Conference on paraoxonases; September 7-10. Debrecen, Hungary.
  • Costa LG, Cole TB, Vitalone A, Furlong CE. 2006. Paraoxonase polymorphisms and toxicity of organophosphates. Toxicology of Organophosphate and Carbamate Pesticides
  • Furlong CE. 2006. A surface plasmon resonance (SPR)-based sensor system for near real-time monitoring of analytes. In: Center for Process Analytical Chemistry Fall Sponser Meeting, November 7-10. Seattle, WA.
  • Furlong CE, Cole TB, Richter RJ, Brophy V, Carlson CS, Rieder R, Nickerson DA, Costa LG, Ranchalis J, Jarvik GP, Lusis AJ, Shih DM, Tward A. 2006. The functional consequences of polymorphisms in the human PON1 gene. In: 2nd International Conference on paraoxonases; September 7-10. Debrecen, Hungary.

2005

  • Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. 2005. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics15(8):589-598.
  • Costa LG, Cole TB, Furlong CE. 2005. Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta Bio-Medica de I Ateneo Parmense 76Suppl.2:50-57.
  • Costa LG, Cole TB, Vitalone A, Furlong CE. 2005. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clinica Chimica Acta352(1-2):37-47.
  • Costa LG, Vitalone A, Cole TB, Furlong CE. 2005. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol69(4):541-550.
  • Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward A, Lusis AJ, Costa LG. 2005. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology26(4):651-659.
  • Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG. 2005. Paraoxonase 1 (PON1) status and risk of insecticide exposure. J Biochem Mol Toxicol19(3):182-183.

2004

  • Costa LG, Kelada SN, Costa-Mallen P, Farin FM, Viernes HA, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H, Furlong CE. 2004. Paraoxonase 2 (PON2) polymorphisms and Parkinson's disease. Neuroscience Research Communications34(3):130-135.
  • Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward A, Lusis AJ, Costa LG. 2004. Role of paraoxonase (PON1) status in pesticide sensitivity; genetic and temporal determinants. Neurotoxicology26(4):651-659.

2003

  • Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. 2003. Expression of human paraoxonase (PON1) during development. Pharmacogenet Genomics13(6):357-364.
  • Costa LG, Cole TB, Furlong CE. 2003. Polymorphisms of paraoxonse (PONl)and their significance in clinical toxicology of organophosphates. Toxicology41(1):37-45.
  • Costa LG, Cole TB, Jarvik GP, Furlong CE. 2003. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med54:371-392.
  • Costa LG, Richter RJ, Li WE, Cole TB, Guizzetti M, Furlong CE. 2003. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers8(1):1-12.
  • Kelada SN, Costa-Mallen P, Checkoway H, Viernes HA, Farin FM, Costa LG, Longstreth WT, Furlong CE, Jarvik GP, Swanson PD. 2003. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry74(4):546-547.

2002

  • Costa LG, Furlong CE. 2002. Perspectives in PONI research. Chapter 10. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Kluwer Academic Publishers, pp.197-210.
  • Costa LG, Li WF, Richter RJ, Shih DM, Lusis AJ, Furlong CE. 2002. PONl and organophosphate toxicity. Chapter 8. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Kluwer Academic Publishers, pp.165-183.
  • Furlong CE, Cole TB, Jarvik GP, Costa LG. 2002. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenet Genomics3(3):341-348.

1993

  • Furlong CE, Costa LG, Hassett C, Richter RJ, Sundstrom JA, Adler DA, Disteche CM, Omiecinski CJ, Chapline CM, Crabb JW, Humbert R. 1993. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact87(1-3):35-48. PMID:8393745

Share This Page:

Page Options:

Request Translation Services